sirukumab sirukumab sirukumab (inn, usan) (developmental code name cnto-136, tentative brand name plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. it acts against the proinflammatory cytokine interleukin 6 (il-6). sirukumabmonoclonal antibodytypewhole antibodysourcehumantargetil6clinical dataatc codel04ac15 (who) identifierscas number1194585-53-9 ndrugbankdb11803 ychemspidernoneunii640443fu93keggd10080chemical and physical dataformulac6450h9926n1690o1998s46molar mass144588.95 g·mol−1 ny (what is this?) (verify) sirukumab is currently under development by johnson & johnson's subsidiary centocor. clinical trials rheumatoid arthritis it has started clinical trials. and reported some phase ii results. in december 2015 three phase iii trials (sirround-d, -h and -t) were collecting data. by feb 2017 sirround-d was considered to have met both co-primary endpoints. other the drug was previously under development for the treatment of depression.